Compare Burlington Stores Inc (BURL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Burlington Stores Inc vs BIO-TECHNE Corp — how do they compare? Burlington Stores Inc trades at $359.42 (market cap $23.38B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Burlington Stores Inc is far larger — about 2.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| BURL | TECH | |
|---|---|---|
Market Cap | $23.38B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $72.29 |
52-Week Low | $242.43 | $43.31 |
Enterprise Value | $28.51B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $368.96, showing slight weakness with a 0.59% decline but remains near recent highs. The stock maintains strong technical momentum with bullish moving averages and trades above key support levels. Fundamentally, the company demonstrates robust earnings performance with three consecutive quarterly beats and improving profitability margins. Recent news highlights Burlington's successful smaller-store strategy driving sales productivity and upgraded analyst ratings.
The outlook remains positive with 94% analyst buy ratings and a $367 consensus target. Growth catalysts include continued store expansion and operational efficiency gains, though risks include competitive retail pressures and potential consumer spending volatility. The stock's premium valuation requires sustained execution to justify current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
